Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (INO) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Inovio Pharmaceuticals, Inc. (INO), featuring income statements, balance sheets, and cash flow data.
Inovio Pharmaceuticals, Inc. (INO) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Inovio Pharmaceuticals, Inc. INO financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $116994.00 | $0.00 | $100762.00 | $0.00 |
| Cost of Revenue | $775829.00 | $0.00 | $828625.00 | $759730.00 |
| Gross Profit | -$658835.00 | $0.00 | -$727863.00 | -$759730.00 |
| Gross Profit Ratio | -$5.63 | $0.00 | -$7.22 | |
| R&D Expenses | $12.89M | $18.73M | $23.09M | $20.91M |
| SG&A Expenses | $7.60M | $8.61M | $10.21M | $9.81M |
| Operating Expenses | $20.49M | $27.35M | $32.47M | $30.73M |
| Total Costs & Expenses | $20.49M | $27.35M | $33.30M | $31.48M |
| Interest Income | $852587.00 | $1.11M | $1.31M | $1.50M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $177833.00 |
| Depreciation & Amortization | $775829.00 | $765858.00 | $828625.00 | $759730.00 |
| EBITDA | -$18.61M | -$24.40M | -$31.41M | -$29.53M |
| EBITDA Ratio | -$159.03 | -$311.71 | ||
| Operating Income | -$20.37M | -$27.35M | -$33.20M | -$31.48M |
| Operating Income Ratio | -$174.11 | -$329.46 | ||
| Other Income/Expenses (Net) | $987882.00 | -$25.14B | $959815.00 | $1.02M |
| Income Before Tax | -$19.38M | -$25.17B | -$32.24M | -$30.47M |
| Income Before Tax Ratio | -$165.66 | -$319.93 | ||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $716454.00 |
| Net Income | -$19.38M | -$25.17B | -$32.24M | -$30.47M |
| Net Income Ratio | -$165.66 | -$319.93 | ||
| EPS | -$0.70 | -$894.28 | -$1.19 | -$1.31 |
| Diluted EPS | -$0.70 | -$894.28 | -$1.19 | -$1.31 |
| Weighted Avg Shares Outstanding | $32.46M | $28.14M | $27.20M | $23.29M |
| Weighted Avg Shares Outstanding (Diluted) | $32.46M | $28.14M | $27.20M | $23.29M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q1 2024 to $116994.00 in Q4 2024. Gross profit remained healthy with margins at -563% in Q4 2024 compared to N/A in Q1 2024. Operating income hit -$20.37M last quarter, sustaining a consistent -17411% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$18.61M. Net income rose to -$19.38M, while earnings per share reached -$0.70. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan